Title:
骨髄増殖性新生物の治療に適した化合物
Document Type and Number:
Japanese Patent JP6479818
Kind Code:
B2
Abstract:
The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibers. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective β3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.
Inventors:
Mendes Ferrer, Simon
Allans Saras, Lorena
Iseln Marin, Hoang
Allans Saras, Lorena
Iseln Marin, Hoang
Application Number:
JP2016541847A
Publication Date:
March 06, 2019
Filing Date:
May 12, 2014
Export Citation:
Assignee:
CNY Foundation Centro National Dainvesti Gaithones Cardio Bascureas Carlos The Third
International Classes:
A61K31/426; A61K31/192; A61K31/216; A61K31/36; A61P35/02; C12Q1/02
Other References:
Urology,2012年,Vol.79,744, e1-7
Leukemia,2013年 1月,Vol.27,p.1236-1244
Leukemia,2013年 1月,Vol.27,p.1236-1244
Attorney, Agent or Firm:
Yusuke Hiraki
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta
Takashima Ejima
Satoshi Fujita
Eiichi Arai
Natsuo Tanaka
Naoko Kikuta
Takashima Ejima